P-174: Clinical study of bortezomib-based regimens of BCD, PAD and VDD for newly diagnosed multiple myeloma – an analysis of 400 cases in a single center of China

Background Objective To investigate the clinical efficacy and safety of bortezomib-based regimens of BCD (bortezomib, cyclophosphamide and dexamethasone), PAD (bortezomib, doxorubicin and dexamethasone) and VDD (bortezomib, pegylated liposomal doxorubicin and dexamethasone). Methods 400 newly diagnosed multiple myeloma (MM) patients enrolled in two prospective non-randomized cohort studies in a single center were retrospectively analyzed from April 2008 to August 2017. Results Among all the patients, 194 cases (48.5%) received BCD, 84 cases (21.0%) received PAD, and 122 cases (30.5%) received VDD. 1) Analysis of clinical features: Serum albumin (ALB) level was lower in the BCD group than the other two (P Conclusion As the bortezomib-based three-drug regimens combined with traditional chemotherapeutic agents, BCD, PAD and VDD can all achieve remission in more than 80% newly diagnosed MM patients as induction therapy. The efficacy and long-term outcomes are comparable between the three regimens. In the aspects of safety, the BCD and VDD groups had a lower risk of grade 3/4 hematological toxicity.